Molecular diagnosis and measurement of minimal residual disease (MRD) in patients
with chronic myeloid leukemia (CML) is essential for clinical management. In the era
of tyrosine kinase inhibitor therapy molecular tests including BCR-ABL1 transcript
monitoring and kinase domain mutation analysis are the main tools used to inform choice
of treatment, appropriate dosage and even whether therapy can be safely withdrawn.
Quantitation of BCR-ABL1 oncogene transcript by real-time quantitative PCR (qPCR)
is currently the gold-standard method for monitoring as it provides superior sensitivity
over karyotyping and fluorescent in situ hybridization (FISH). Here we describe step-by-step
methods of RNA conversion to cDNA along with the qPCR protocol which is used in one
of the main reference laboratories for this test.
